Section Arrow
Quote
PRTA.NASDAQ
- Prothena Corp
Quotes are at least 15-min delayed:2026/05/27 15:46 EDT
After Hours
Last
 --
-- (--)
Bid
--
Ask
--
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 10.085
+0.025 (+0.25%)
Day High 
10.26 
Prev. Close
10.06 
1-M High
11.8 
Volume 
457.26K 
Bid
10.08
Ask
10.09
Day Low
10.005 
Open
10.11 
1-M Low
9.02 
Market Cap 
526.67M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 9.6 
20-SMA 10.21 
50-SMA 10.05 
52-W High 11.8 
52-W Low 4.53 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.81/-0.64
Enterprise Value
532.16M
Balance Sheet
Book Value Per Share
5.97
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.68M
Operating Revenue Per Share
2.69
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BRTXBioRestorative Therapies0.4145+0.1647+65.93%-- 
After Hours -- -- --
AIMAIM ImmunoTech Inc.0.4066+0.1739+74.73%-- 
After Hours -- -- --
SNGXSoligenix Inc.0.8955+0.3825+74.56%-- 
After Hours -- -- --
HOTHHoth Therapeutics1.4123+0.704+99.39%-- 
After Hours -- -- --
OTLKOutlook Therapeutics0.5559+0.1557+38.91%-- 
After Hours -- -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.